Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04793932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)

Study acronym: CASSANDRA
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Phase 2 to Phase 3v2 Show 6 more changesShow less
    • Primary completion date changed from estimate of Nov 2021 to Mar 15, 2025
    • Primary endpoints revised (2)
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Nov 2023 to Jan 31, 2026
    • Eligibility criteria expanded, about 9 words
    • Site details revised at 22 of 22 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main aim of this study is to compare the efficacy of short-course versus long-course pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.
Trial Details
NCT Number NCT04793932
Lead Sponsor Associazione Italiana per lo Studio del Pancreas
Collaborators: High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Conditions
(from sponsor)		 Pancreas Ductal Adenocarcinoma
Enrollment 261 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov